Policy & Regulation
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
19 November 2026 -

Swedish pharmaceutical company Dicot Pharma AB (Nasdaq First North:DICOT) announced on Thursday that it has received regulatory approval to initiate its phase 2b clinical study of LIB-01 in the European Union, with Sweden becoming the first participating EU country to grant authorisation. The clinical trial application also covers France and the Netherlands.

The study, which recently commenced in the United States, will evaluate LIB-01 as a potential treatment for erectile dysfunction through repeated monthly dosing at different dose levels. Following completion of the initial US study phase, Dicot Pharma expects to begin dosing participants in the EU during the efficacy evaluation phase.

The ongoing first part of the study aims to establish the highest dose for the efficacy assessment and is expected to conclude in the first quarter of 2027.

The adaptive phase 2b study will involve at least 200 participants across all severities of erectile dysfunction, evaluating planned doses of 25 mg, 50 mg and a higher dose to be determined. Results are expected to support dose selection for phase 3 development.

Login
Username:

Password: